Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
This study will examine the effect intravenously administered rigosertib has on the relationship between bone marrow blasts response and overall survival in myelodysplastic syndromes (MDS) patients who have 5-30% bone marrow blasts and who progressed on or after treatment with azacitidine or decitabine.
Critère d'inclusion
- Myelodysplastic syndromes,Refractory Anemia With Excess Blasts,Chronic myelomonocytic leukemia,Cytopenia